Insulin glargine and lixisenatide Subcutaneous and Pazopanib Hydrochloride
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and Pazopanib Hydrochloride and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: pazopanib
Brand name: Votrient
Synonyms: Pazopanib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-PB Hyos Elixir
- Insulin glargine and lixisenatide Subcutaneous-PCE
- Insulin glargine and lixisenatide Subcutaneous-PCE Dispertab
- Insulin glargine and lixisenatide Subcutaneous-PCM-LA
- Insulin glargine and lixisenatide Subcutaneous-Pedia Care Multi-Symptom Cold
- Insulin glargine and lixisenatide Subcutaneous-Pedia Poly-Vite Drops with Iron
- Pazopanib Hydrochloride-Insulin glargine, recombinant Subcutaneous
- Pazopanib Hydrochloride-Insulin glulisine
- Pazopanib Hydrochloride-Insulin Glulisine (Cartridges and Pens)
- Pazopanib Hydrochloride-Insulin Glulisine (Vials)
- Pazopanib Hydrochloride-Insulin glulisine Subcutaneous
- Pazopanib Hydrochloride-Insulin human inhaled Inhalation